At its core, glutamylation involves the enzymatic addition of glutamate moieties to target proteins, a process that can be reversed by specific enzymes that remove them. This reversibility is what distinguishes glutamylation from a static structural feature and elevates it to the status of a genuine signaling modification. By modulating protein activity, stability, subcellular localization, and molecular interactions, glutamylation allows cells to respond rapidly and reversibly to internal and external cues. The review emphasizes that this dynamic quality, long appreciated in the context of microtubule regulation, applies equally to a growing list of non-structural substrates that participate in signal transduction, gene expression, and immune defense.

The enzymatic machinery responsible for glutamylation comprises two opposing families. The tubulin tyrosine ligase-like (TTLL) family catalyzes the initiation and elongation of glutamate chains on the C-terminal tails of alpha- and beta-tubulin, while cytosolic carboxypeptidases (CCPs) mediate the trimming and complete removal of these chains through deglutamylation. This push-and-pull system creates a finely tuned equilibrium that determines the glutamylation state of individual proteins at any given moment. Disruption of this balance, whether through mutation, altered expression, or pathological stress, can have profound consequences for cellular function, and the review highlights how imbalances in TTLL and CCP activity are increasingly linked to human disease.

The classical territory of glutamylation remains the cytoskeleton. Tubulin glutamylation fine-tunes microtubule properties and contributes to a remarkable range of cellular processes, including ciliary function, neuronal development and function, endoplasmic reticulum organization, centrosome and mitotic spindle dynamics, and overall cytoskeletal organization. In cilia, the hair-like projections that sense fluid flow and transmit developmental signals, precise glutamylation patterns are essential for structural integrity and signaling fidelity. In neurons, where microtubules form the scaffolding of axons and dendrites, glutamylation helps maintain the specialized architecture required for long-distance communication. During cell division, the modification influences centrosome behavior and spindle assembly, ensuring accurate chromosome segregation.

What has transformed the field, however, is the discovery that glutamylation extends well beyond tubulin. The review catalogs a growing repertoire of nontubulin substrates whose modification by glutamate addition alters fundamental cellular decisions. Among the most consequential are cGAS, the cytosolic DNA sensor that initiates innate immune responses; KLF4, a transcription factor governing cell-fate determination; IL-7Rα, a receptor subunit critical for lymphocyte development; BAP1, a tumor suppressor involved in chromatin regulation; TAB1, a signaling adaptor in inflammatory pathways; and YAP1, a transcriptional coactivator central to organ growth and regeneration. Glutamylation of these molecules modulates innate immunity, cell-fate choices, hematopoietic homeostasis, metabolic adaptation, tumor progression, and immune evasion.

The implications for immunology are particularly striking. Modification of cGAS, the enzyme that detects cytosolic DNA and triggers antiviral and antimicrobial defenses, demonstrates that glutamylation can tune the sensitivity of the innate immune system. Alterations in IL-7Rα glutamylation affect signaling through a receptor essential for T-cell and B-cell development, linking the modification directly to hematopoietic homeostasis. On the other side of the immune equation, the review notes that glutamylation-dependent changes can contribute to immune evasion, a process by which tumor cells and other threats avoid detection and destruction by the immune system. This dual role, as both a regulator of immune activation and a potential contributor to immune escape, makes the glutamylation machinery a compelling target for therapeutic intervention.

In oncology, the connection between glutamylation and cancer is reinforced through substrates such as BAP1 and YAP1. BAP1, a deubiquitinase with tumor-suppressive functions, and YAP1, a key effector of the Hippo signaling pathway that controls cell proliferation and organ size, are both subject to glutamylation-dependent regulation. TAB1, which participates in inflammatory signaling cascades, adds another layer by connecting the modification to the tumor microenvironment and inflammation-driven malignancy. The review proposes that these substrates, and the enzymes that modify them, could serve as biomarkers for disease progression and as pharmacological targets for novel cancer therapies.

Beyond cancer, the reach of glutamylation into neurodevelopment, metabolism, and cell-fate decisions suggests a modification of extraordinary breadth. KLF4, whose glutamylation influences cell-fate determination, sits at the intersection of stem cell biology and differentiation. Metabolic adaptation, the ability of cells to reprogram energy use in response to nutrient availability and stress, is also modulated through glutamylation-dependent mechanisms. The review integrates these threads into a coherent argument: glutamylation is not a niche modification confined to microtubule tails but a versatile signaling-related post-translational modification that operates across cellular compartments and biological contexts.

The therapeutic opportunities highlighted in the review are twofold. First, targeting TTLL and CCP enzymes directly offers a strategy to modulate glutamylation states in disease, whether by inhibiting excessive modification in tumors or restoring deficient modification in degenerative conditions. Second, the glutamylation status of specific substrates, such as cGAS, YAP1, or BAP1, could serve as biomarkers that guide diagnosis, prognosis, and treatment selection. The authors discuss emerging pharmacological approaches that exploit these possibilities, positioning the glutamylation system as a frontier for drug discovery.

By synthesizing evidence across cytoskeletal biology, cell signaling, and disease mechanisms, the review marks a conceptual shift in how the scientific community understands protein glutamylation. What began as a description of microtubule decoration has matured into a framework that connects cilia, neurons, dividing cells, immune sentinels, and cancer cells through a shared chemical language of reversible glutamate addition and removal. As research continues to uncover new substrates and refine the tools for measuring and manipulating glutamylation, the modification is likely to assume an increasingly prominent place in the study of cellular regulation and in the development of therapies for conditions ranging from neurodevelopmental disorders to metastatic cancer.

Subject of Research: Protein glutamylation as a reversible post-translational modification regulating cytoskeletal and signaling pathways

Article Title: Protein glutamylation: From cytoskeleton to signaling

Article References: Protein glutamylation: From cytoskeleton to signaling. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: protein glutamylation, post-translational modification, TTLL enzymes, cytosolic carboxypeptidases, tubulin code, cGAS, YAP1, BAP1, cilia, tumor progression, immune evasion, biomarkers

The clinical story began innocuously. After a hospital admission for severe community-acquired pneumonia, the man was referred to a London outpatient clinic for persistent shortness of breath on climbing stairs and unintentional weight loss. Follow-up chest radiographs arranged to confirm that his pneumonia had resolved revealed something unexpected: a persistent right-sided pleural effusion, an abnormal collection of fluid in the space surrounding the lung, accompanied by collapse of the underlying lung tissue. What might have been dismissed as a lingering complication of infection instead became the first clue to a far more serious process.

Computed tomography imaging escalated the concern. The scan demonstrated a moderate right-sided pleural effusion with circumferential nodular thickening of the pleura, the delicate membrane that envelops the lung, along with enlarged lymph nodes near the heart and in the right hilum. Fluorodeoxyglucose-positron emission tomography, a scanning technique that highlights metabolically active tissue, showed diffuse uptake across the pleura with moderate avidity, and identified an enlarged intercostal lymph node that was accessible for biopsy. Formal staging placed the tumour at T3N1M0, indicating locally advanced disease with regional lymph node involvement but no distant spread.

Fluid drawn from the chest under ultrasound guidance was a cloudy yellow exudate, with a protein level of 54 grams per litre, a fluid-to-serum protein ratio of 0.72, glucose of 3.8 millimoles per litre and lactate dehydrogenase of 490 units per litre. Cytology showed lymphocytosis but, crucially, no malignant cells. The diagnostic breakthrough came from the intercostal lymph node itself. Histopathology revealed morphology and an immunoprofile consistent with an epithelioid-type malignant mesothelioma with lymphovascular invasion, and adenocarcinoma markers were negative. The tumour cells expressed calretinin, WT-1 and D2-40 while testing negative for TTF-1, a marker profile that firmly pointed to mesothelioma rather than lung adenocarcinoma.

Immunohistochemistry demonstrated retained expression of BRCA-1 associated protein, known as BAP1, and germline testing for BAP1 tumour predisposition syndrome came back negative. This mattered because BAP1 loss is a hallmark of many mesotheliomas and because inherited mutations in BAP1 define a recognised cancer predisposition syndrome. Broader germline panel testing was not performed, however, leaving open the possibility of other inherited susceptibility genes. After discussion by the lung cancer multidisciplinary team and referral to the regional mesothelioma service, the tumour was deemed inoperable, and the patient began combination immunotherapy with nivolumab and ipilimumab, a checkpoint inhibitor regimen that has transformed outcomes for some patients with advanced disease.

The puzzle was the exposure history. The patient was born in Kandahar, Afghanistan, moved to Kabul at age three, relocated to Peshawar in Pakistan at thirteen, and immigrated to the United Kingdom at sixteen. He had no identifiable occupational exposure to asbestos, no para-occupational exposure through household contacts, and no memory of living near an asbestos mine. In Britain he worked as a hospital biochemist, an occupation far removed from the traditional asbestos trades. The reporting team, led by Sophie Mounouchos and colleagues writing in Respirology Case Reports, looked instead to his childhood environments, and what they found was a growing body of evidence linking environmental asbestos exposure in Afghanistan and Pakistan to mesothelioma and pleural disease.

In Afghanistan, pleural plaques, thickened patches on the pleura that serve as fingerprints of asbestos exposure, have been reported in a 51-year-old Kabul resident with no occupational exposure. The authors of that report proposed environmental exposure from the neighbouring Loghar region, where natural deposits of tremolite, an amphibole asbestos, have been documented. Kabul also used asbestos-containing materials during the 1970s, including asbestos-cement piping and sheeting. During the 1980s the city suffered repeated structural damage in the Soviet-Afghan conflict, and armed conflict may have mechanically disrupted those materials, releasing airborne fibres, although the researchers caution that the importance of this mechanism remains uncertain.

Pakistan may have added a second layer of exposure. Peshawar lies within Khyber Pakhtunkhwa province, which contains ninety percent of Pakistan’s naturally occurring asbestos deposits, and asbestos-containing construction materials remain widely used in the country. A case series has identified a heavy burden of malignant mesothelioma in the region, thought to be associated with the high concentration of asbestos deposits, and concern about rising diagnoses in younger people is reinforced by a 2011 report of a 26-year-old woman in northern Pakistan diagnosed with the disease despite no occupational exposure. The interval between the patient’s early childhood residence in Kabul and Peshawar and his diagnosis at age forty sits squarely within the recognised latency periods for mesothelioma, lending biological plausibility to the proposed pathway.

The case also illuminates the role of genetics. The environmental mesothelioma outbreak in Turkey linked to erionite, an asbestiform mineral, revealed familial clustering and indirectly led to the identification of the BAP1-associated tumour predisposition syndrome. In a United States cohort of 198 mesothelioma patients, twelve percent carried susceptible germline mutations, notably among younger patients, and BAP1 accounted for only a quarter of the pathogenic mutations found across thirteen cancer-susceptibility genes. Because broader germline testing was not performed in the London case, inherited susceptibility cannot be fully excluded. Together these threads suggest that mesothelioma in the young may represent a distinct entity, with environmental exposure and genetic predisposition interacting in ways that differ from the classic occupational disease of older men.

The implications reach well beyond a single patient. In the United Kingdom, the decline of heavy industry and progressively stricter exposure legislation have driven occupational mesothelioma deaths downward, bringing environmental exposures into sharper focus. While men bear the bulk of disease across all ages, reflecting their historically greater occupational exposure, the gender distribution among those diagnosed under forty is far more even, hinting that other causal factors dominate in the young. The authors argue that clinicians in high-income countries should consider earlier-life environmental and residential exposures acquired overseas, particularly in younger mesothelioma patients who lack conventional occupational histories. Migration to high-resource healthcare settings, they suggest, may be an important mechanism for recognising environmental mesothelioma that would otherwise go undiagnosed in lower-resource settings, and understanding the interplay between inherited susceptibility and environmental fibre exposure may prove essential to unravelling this rare and devastating cancer in the young.

Subject of Research: Environmental asbestos exposure and early-onset malignant pleural mesothelioma

Article Title: Environmental Asbestos Exposure as a Possible Pathway to Early‐Onset Pleural Mesothelioma: A Case From Afghanistan and Pakistan to London

Article References: Mounouchos, S., Aggarwal, A., Nafees, A. A., Johnson, E., Cullinan, P., & Reynolds, C. (2026). Environmental Asbestos Exposure as a Possible Pathway to Early‐Onset Pleural Mesothelioma: A Case From Afghanistan and Pakistan to London. Respirology Case Reports, 14(10), Article e70774. https://doi.org/10.1002/rcr2.70774

Image Credits: AI Generated

DOI: 10.1002/rcr2.70774

Keywords: mesothelioma, asbestos, environmental exposure, Afghanistan, Pakistan, pleural effusion, BAP1, genetic susceptibility, early-onset cancer, immunotherapy, tremolite, Khyber Pakhtunkhwa